Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase Ib/III Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Patients With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy

Summary

The purpose of this phase Ib/III study is to evaluate the safety and feasibility of RYZ101 in comparison to standard of care therapy (Everolimus, Sunitinib, Octreotide, Lanreotide) in patients with advanced staged, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment.

General Information

NCT#: NCT05477576
Study ID: RYZ101-301
Trial Phase: Phase I/II

Trial Sponsor: RayzeBio, Inc.
Therapies Used in This Trial: Everolimus, Octreotide Acetate, Lanreotide, Sunitinib, RYZ101

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search